Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review
Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
Avidity Stock Soars on Collaboration Deal With Bristol Myers
Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.
Avidity Biosciences leaps on Bristol-Myers research tie-up
Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY). The pact is focused on the discovery, d...
Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better
Bristol-Myers Squibb Company is down 40%, while the market is up 20%. The reason is the collapse in its growth outlook created by patent cliffs. Despite some amazing growth in new drugs, Bristol's ...
Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments
Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the pot...
3 Resilient Stocks with Massive Potential to Boost Your Wealth
Although the stock market whipsawed investors over the past few years, it showed its resilience by bouncing sharply higher after the pandemic collapse. As it has for more than a century, every doub...
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale
When bad news happens to good companies, it just might be a signal to consider buying shares. Johnson Controls has a solid business, but its stock is down thanks to less-than-ideal guidance.
Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters
Based on the strong print of the major indices since late last month, the idea of deliberately targeting reliable stocks for a volatile market might seem overkill. In the past 30 days, the benchmar...
Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug
Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use ...
Why Bristol Myers Squibb Stock Is Fading Today
Bayer announced that it is halting a late-stage trial for asundexian, a high-profile candidate for cardiovascular disease. Bristol Myers Squibb and Johnson & Johnson are co-developing a therapy tha...
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
Bristol-Myers Squibb (NYSE: BMY ) stock is falling on Monday after a couple of updates that are weighing on BMY shares today. The first bit of news worth noting are results from a clinical trial of...
Bristol Myers Squibb Stock Falls After Drug Approval Delayed
Abecma, developed with 2seventy Bio, won't be approved for earlier treatments of a certain kind of blood cancer by a Dec. 16 deadline.
Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decision
Bristol-Myers Squibb Co (NYSE:BMY) shares fell almost 5% after the company announced that a Food and Drug Administration (FDA) decision on the use of its blood cancer therapy Abecma, developed with...
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment
Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential ap...
Related Companies